Kailera Therapeutics, Inc. (KLRA) Ownership
KLRA ownership summary
as of October 18, 2026- Institutions
- 90.4% of shares outstanding
- Insiders
- 8.91% of shares outstanding
- Shares outstanding
- 129.6M
- Float
- 58.5M shares available to trade
- Short interest
- 6.70% 8.7M shares short
- Days to cover
- 7.26 short interest up 45.6% vs prior month
- Institutions 90.44%
- Insiders 8.91%
- Other investors 0.65%
KLRA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Bain Capital Investors LLC | 20.25% | 26.3M | $295.4M | +26.3M (0.0%) | June 30, 2026 |
| 2 | Bain Capital Life Sciences Investors, LLC | 17.42% | 22.6M | $254.1M | +22.6M (0.0%) | June 30, 2026 |
| 3 | RTW INVESTMENTS, LLC | 8.31% | 10.8M | $121.2M | +10.8M (0.0%) | June 30, 2026 |
| 4 | Canada Pension Plan Investment Board | 5.63% | 7.3M | $82.2M | +7.3M (0.0%) | June 30, 2026 |
| 5 | Atlas Venture Life Science Advisors, LLC | 3.99% | 5.2M | $58.2M | +5.2M (0.0%) | June 30, 2026 |
| 6 | FMR Inc | 3.06% | 4.0M | $44.7M | +4.0M (0.0%) | June 30, 2026 |
| 7 | BlackRock Inc | 3.03% | 3.9M | $44.2M | +3.9M (0.0%) | June 30, 2026 |
| 8 | T. Rowe Price Associates, Inc. | 2.73% | 3.5M | $39.8M | +3.5M (0.0%) | June 30, 2026 |
| 9 | Citadel Advisors Llc | 2.50% | 3.2M | $36.5M | +3.2M (0.0%) | June 30, 2026 |
| 10 | Adage Capital Partners Gp LLC | 2.47% | 3.2M | $36.1M | +3.2M (0.0%) | June 30, 2026 |
| 11 | Wellington Management Company LLP | 2.25% | 2.9M | $32.8M | +2.9M (0.0%) | June 30, 2026 |
| 12 | Royalty Pharma Sub-Manager, LLC | 1.89% | 2.5M | $27.6M | +2.5M (0.0%) | June 30, 2026 |
| 13 | Siren, L.L.C. | 1.71% | 2.2M | $24.9M | +2.2M (0.0%) | June 30, 2026 |
| 14 | Vanguard Capital Management, LLC | 1.31% | 1.7M | $19.1M | +1.7M (0.0%) | June 30, 2026 |
| 15 | Vanguard Portfolio Management, LLC | 1.27% | 1.7M | $18.6M | +1.7M (0.0%) | June 30, 2026 |
| 16 | Geode Capital Management, LLC | 0.87% | 1.1M | $12.7M | +1.1M (0.0%) | June 30, 2026 |
| 17 | Frazier Life Sciences Management, L.P. | 0.85% | 1.1M | $12.4M | +1.1M (0.0%) | June 30, 2026 |
| 18 | Farallon Capital Management, L.L.C. | 0.85% | 1.1M | $12.4M | +1.1M (0.0%) | June 30, 2026 |
| 19 | Trails Edge Capital Partners, LP | 0.76% | 985K | $11.1M | +984,786 (0.0%) | June 30, 2026 |
| 20 | UBS Group AG | 0.75% | 973K | $10.9M | +972,683 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 20 holders added 106.2M shares and 0 cut 0.
KLRA top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Health Care Inv | 1.69% | 2.2M | $24.7M | +2.2M (0.0%) | June 30, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 0.95% | 1.2M | $13.8M | −23,500 (−1.9%) | September 30, 2026 |
| 3 | iShares Russell 2000 ETF | 0.93% | 1.2M | $13.5M | −13,824 (−1.1%) | September 30, 2026 |
| 4 | Vanguard MStar Total Stk Mkt Idx Invest | 0.91% | 1.2M | $13.3M | — | August 31, 2026 |
| 5 | T. Rowe Price Health Sciences | 0.84% | 1.1M | $12.3M | −435,700 (−28.5%) | August 31, 2026 |
| 6 | Vanguard Small Cap Index | 0.66% | 853K | $9.6M | +1,013 (+0.1%) | August 31, 2026 |
| 7 | Columbia Small Cap Growth Inst | 0.60% | 784K | $8.8M | — | August 31, 2026 |
| 8 | Fidelity Growth Company Fund | 0.54% | 701K | $7.9M | — | August 31, 2026 |
| 9 | Fidelity Select Biotechnology | 0.49% | 632K | $7.1M | +5,300 (+0.8%) | August 31, 2026 |
| 10 | Eventide Healthcare & Life Sciences I | 0.48% | 617K | $6.9M | +616,720 (0.0%) | June 30, 2026 |
| 11 | Fidelity Blue Chip Growth | 0.45% | 587K | $6.6M | — | August 31, 2026 |
| 12 | Fidelity Small Cap Index | 0.39% | 504K | $5.7M | +4,080 (+0.8%) | July 31, 2026 |
| 13 | Vanguard MStar Small Cap Growth Indx Inv | 0.38% | 487K | $5.5M | −2,112 (−0.4%) | August 31, 2026 |
| 14 | T. Rowe Price Integrated US Sm Gr Eq | 0.37% | 475K | $5.3M | — | August 31, 2026 |
| 15 | Federated Hermes Kaufmann Small Cap A | 0.33% | 434K | $4.9M | +434,069 (0.0%) | June 30, 2026 |
| 16 | T. Rowe Price New Horizons | 0.26% | 335K | $3.8M | −13,693 (−3.9%) | August 31, 2026 |
| 17 | BlackRock Health Sciences Opps Inv A | 0.26% | 334K | $3.8M | — | August 31, 2026 |
| 18 | iShares Russell 2000 Growth ETF | 0.23% | 294K | $3.3M | −372 (−0.1%) | September 30, 2026 |
| 19 | Vanguard Russell 2000 ETF | 0.20% | 265K | $3.0M | +6,374 (+2.5%) | August 31, 2026 |
| 20 | Franklin Biotechnology Discv A(acc)USD | 0.20% | 254K | $2.9M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
KLRA insider transactions
latest 3| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-20 | Adam Koppel | Buy | $16.00 | 1,562,500 | $25.0M |
| 2026-04-20 | Andrew T Kaplan | Buy | $16.00 | 8,398,438 | $134.4M |
| 2026-04-20 | Rtw Investments, Lp | Buy | $16.00 | 500,000 | $8.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
Who owns KLRA
Institutional investors own 90.4% of Kailera Therapeutics's shares and insiders 8.91%. The largest holder is Bain Capital Investors LLC with 20.25% of the shares (26.3M), as of June 30, 2026. Among the top 20 institutions, 20 added shares and 0 reduced their stake in the latest filings. Short interest is 6.70% of the float, or 7.26 days of average trading volume.
Related: KLRA analyst forecast. See the KLRA stock overview for the latest quote and news.
KLRA ownership FAQ
Who owns the most Kailera Therapeutics stock?
The largest shareholders of Kailera Therapeutics are Bain Capital Investors LLC (20.25%), Bain Capital Life Sciences Investors, LLC (17.42%), RTW INVESTMENTS, LLC (8.31%), Canada Pension Plan Investment Board (5.63%), Atlas Venture Life Science Advisors, LLC (3.99%).
What percentage of Kailera Therapeutics is owned by institutions?
Institutions hold 90.4% of Kailera Therapeutics's shares outstanding; insiders hold 8.91%.
Which funds own Kailera Therapeutics?
The largest fund holders of Kailera Therapeutics are Vanguard Health Care Inv (1.69%), State Street® SPDR® S&P® Biotech ETF (0.95%), iShares Russell 2000 ETF (0.93%), Vanguard MStar Total Stk Mkt Idx Invest (0.91%), T. Rowe Price Health Sciences (0.84%).
What is Kailera Therapeutics's short interest?
8.7M shares of Kailera Therapeutics were sold short, 6.70% of the float; at the average daily volume it would take 7.26 days to cover.
Are insiders buying or selling Kailera Therapeutics?
Of the latest 3 reported insider transactions in Kailera Therapeutics (since April 20, 2026), 3 were purchases and 0 were sales.
How many shares of Kailera Therapeutics are outstanding?
Kailera Therapeutics has 129.6M shares outstanding, of which 58.5M are in the public float.